Amphastar Pharmaceuticals Comprehensive Income 2012-2024 | AMPH

Amphastar Pharmaceuticals comprehensive income from 2012 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Amphastar Pharmaceuticals Annual Comprehensive Income
(Millions of US $)
2023 $-8
2022 $-9
2021 $-7
2020 $-4
2019 $-5
2018 $-4
2017 $-2
2016 $-5
2015 $-2
2014 $-2
2013 $
2012 $
2011 $
2009 $
Amphastar Pharmaceuticals Quarterly Comprehensive Income
(Millions of US $)
2024-06-30 $-9
2024-03-31 $-9
2023-12-31 $-8
2023-09-30 $-8
2023-06-30 $-8
2023-03-31 $-8
2022-12-31 $-9
2022-09-30 $-10
2022-06-30 $-9
2022-03-31 $-7
2021-12-31 $-7
2021-09-30 $-6
2021-06-30 $-5
2021-03-31 $-6
2020-12-31 $-4
2020-09-30 $-4
2020-06-30 $-5
2020-03-31 $-5
2019-12-31 $-5
2019-09-30 $-6
2019-06-30 $-4
2019-03-31 $-4
2018-12-31 $-4
2018-09-30 $-4
2018-06-30 $-3
2018-03-31 $-1
2017-12-31 $-2
2017-09-30 $-3
2017-06-30 $-3
2017-03-31 $-4
2016-12-31 $-5
2016-09-30 $-3
2016-06-30 $-3
2016-03-31 $-2
2015-12-31 $-2
2015-09-30 $-4
2015-06-30 $-4
2015-03-31 $-5
2014-12-31 $-2
2014-09-30 $-2
2014-06-30 $-0
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.438B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.120B 6.83
Dr Reddy's Laboratories (RDY) India $13.079B 19.59
BridgeBio Pharma (BBIO) United States $5.045B 0.00
Bausch Health Cos (BHC) Canada $2.956B 2.23
Supernus Pharmaceuticals (SUPN) United States $1.771B 357.00
Taysha Gene Therapies (TSHA) United States $0.449B 73.00
Personalis (PSNL) United States $0.315B 0.00
Assembly Biosciences (ASMB) United States $0.117B 0.00
Acasti Pharma (ACST) Canada $0.028B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00